IMV (TSE:IMV – Get Rating) is scheduled to release its earnings data before the market opens on Thursday, March 16th. Analysts expect IMV to post earnings of C($1.25) per share for the quarter.
IMV Trading Down 2.8 %
Shares of IMV stock opened at C$0.70 on Tuesday. The stock has a market cap of C$8.18 million, a P/E ratio of -0.10 and a beta of 1.24. The stock’s 50 day simple moving average is C$2.38 and its 200-day simple moving average is C$4.37. IMV has a 1-year low of C$0.68 and a 1-year high of C$19.30. The company has a debt-to-equity ratio of 1,231.01, a current ratio of 2.80 and a quick ratio of 2.32.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a “buy” rating and set a C$65.00 price objective on shares of IMV in a research report on Wednesday, December 21st.
IMV Company Profile
IMV Inc operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer.
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.